TABLE 2.

In vitro susceptibilities of 601 clinical isolates of C. glabrata to seven antifungal agents stratified by geographic locationa

Antifungal agentLocationbMIC (μg/ml)c% SdNo. of strains for which MIC (μg/ml) was:
50900.030.060.120.250.51248163264
Amphotericin BN. Am.1280.4915981446221
L. Am.1263.811323201
Eur.1273.321327663051
A-Pac.1264.9131432252
FlucytosineN. Am.0.060.1299.4220104211111
L. Am.0.060.1210032242
Eur.0.060.1298.58745111
A-Pac.0.060.1298.7433121
FluconazoleN. Am.86464.03338492741134
L. Am.81662.1715141822
Eur.81665.21240363647
A-Pac.81680.5422361023
PosaconazoleN. Am.0.5282.51744129923411211
L. Am.1286.225152871
Eur.0.5288.9318554412111
A-Pac.0.5190.973528511
RavuconazoleN. Am.0.25287.3276910756301714101
L. Am.0.25194.814111815621
Eur.0.25195.62163437271324
A-Pac.0.25193.54744143221
VoriconazoleN. Am.0.25190.3145106104281514144
L. Am.0.250.596.6271718842
Eur.0.120.595.6220523615433
A-Pac.0.250.596.12824308212
CaspofungineN. Am.0.030.061001911112252
L. Am.0.030.06100411615
Eur.0.030.061009829521
A-Pac.0.030.06100472622
  • a All isolates tested by broth microdilution according to NCCLS M27 A2 guidelines (18) or by Etest (amphotericin B).

  • b Abbreviations for locations: N. Am., North America (21 sites, 331 isolates); L. Am., Latin America (8 sites, 58 isolates); Eur., Europe (19 sites, 135 isolates); A-Pac., Asia-Pacific (11 sites, 77 isolates).

  • c 50 and 90, MIC50 and MIC90, respectively.

  • d Percentage of strains susceptible at MICs of ≤8 μg/ml (fluconazole), ≤4 μg/ml (flucytosine), or ≤1 μg/ml (all other agents).

  • e Caspofungin MICs read as the lowest concentration at which prominent inhibition (∼50%) is observed at 24 h of incubation (Pfaller et al., submitted).